RU2008130893A - Адипогенные аденовирусы как биомаркеры заболеваний - Google Patents
Адипогенные аденовирусы как биомаркеры заболеваний Download PDFInfo
- Publication number
- RU2008130893A RU2008130893A RU2008130893/13A RU2008130893A RU2008130893A RU 2008130893 A RU2008130893 A RU 2008130893A RU 2008130893/13 A RU2008130893/13 A RU 2008130893/13A RU 2008130893 A RU2008130893 A RU 2008130893A RU 2008130893 A RU2008130893 A RU 2008130893A
- Authority
- RU
- Russia
- Prior art keywords
- adenovirus
- individual
- adipogenic
- sample
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/075—Adenoviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75340205P | 2005-12-27 | 2005-12-27 | |
| US60/753,402 | 2005-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008130893A true RU2008130893A (ru) | 2010-02-10 |
Family
ID=38610014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008130893/13A RU2008130893A (ru) | 2005-12-27 | 2006-12-27 | Адипогенные аденовирусы как биомаркеры заболеваний |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US7442511B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2390372A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009521707A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080114683A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101389768B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006342053A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0620755A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2635269A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2008008453A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2008130893A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007120362A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507418B2 (en) * | 2005-09-09 | 2009-03-24 | Obetech, Llc | Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes |
| WO2007120362A2 (en) * | 2005-12-27 | 2007-10-25 | Obetech, Llc | Adipogenic adenoviruses as a biomarker for disease |
| US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| JP2009156254A (ja) * | 2007-12-05 | 2009-07-16 | Ibiden Co Ltd | 排気ガス処理体の保持シール部材及び排気ガス処理装置 |
| SI2268618T1 (sl) | 2008-03-03 | 2015-09-30 | Novartis Ag | Spojine in sestavki kot modulatorji aktivnosti TLR |
| WO2010011440A2 (en) * | 2008-06-16 | 2010-01-28 | Obetech Llc | Diagnosis and treatment of lipogenic adenovirus infection associated with adipose tissue hypertrophy |
| CA2765112A1 (en) | 2009-06-10 | 2010-12-16 | Novartis Ag | Benzonaphthyridine-containing vaccines |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| US9950062B2 (en) | 2009-09-02 | 2018-04-24 | Glaxosmithkline Biologicals Sa | Compounds and compositions as TLR activity modulators |
| WO2011050299A2 (en) * | 2009-10-22 | 2011-04-28 | Obetech Llc | Adenovirus infection in animals |
| WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
| US8585588B2 (en) | 2009-11-18 | 2013-11-19 | Nohands, Llc | Method and system for preventing virus-related obesity and obesity related diseases |
| JP5814933B2 (ja) | 2009-12-15 | 2015-11-17 | ノバルティス アーゲー | 免疫増強化合物の均質な懸濁物およびその使用 |
| EA031379B1 (ru) | 2010-03-23 | 2018-12-28 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
| WO2011119915A2 (en) * | 2010-03-25 | 2011-09-29 | Obetech Llc | Method for detecting lipogenic adenovirus |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| EP2590665B1 (en) * | 2010-07-08 | 2015-09-16 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease |
| US20130178517A1 (en) * | 2010-07-09 | 2013-07-11 | Richard L. Atkinson | Methods And Compositions For Treatment Of Lipogenic Virus Related Conditions |
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| US9827190B2 (en) | 2013-02-01 | 2017-11-28 | Glaxosmithkline Biologicals Sa | Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists |
| JP2017537145A (ja) | 2014-11-05 | 2017-12-14 | ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーThe United States Of America As Represented By The Secretary Of The Navy | カンピロバクター・ジェジュニに対する合成抗原コンストラクト |
| BR112020016314A2 (pt) | 2018-02-12 | 2020-12-15 | Inimmune Corporation | Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular |
| EP3861348A4 (en) * | 2018-10-05 | 2022-07-20 | Minomic International Ltd. | BIOMARKER COMBINATIONS FOR DETERMINING AGGRESSIVE PROSTATE CANCER |
| KR20230117105A (ko) | 2020-11-04 | 2023-08-07 | 엘리고 바이오사이언스 | 큐티박테리움 아크네스 재조합 파지, 그의 제조 방법 및 용도 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU692152B2 (en) * | 1993-03-17 | 1998-06-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments |
| AU6884298A (en) * | 1997-04-04 | 1998-10-30 | Obetech, Llc | Viral obesity methods and compositions |
| JP2000072800A (ja) * | 1998-08-26 | 2000-03-07 | Toagosei Co Ltd | 抗アデノウイルス37型モノクローナル抗体及びその用途 |
| ES2472325T3 (es) * | 2005-11-30 | 2014-06-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Gen y proteína del adenovirus 36 E4 orf 1 y sus usos |
| WO2007120362A2 (en) * | 2005-12-27 | 2007-10-25 | Obetech, Llc | Adipogenic adenoviruses as a biomarker for disease |
-
2006
- 2006-12-27 WO PCT/US2006/062632 patent/WO2007120362A2/en not_active Ceased
- 2006-12-27 US US11/616,799 patent/US7442511B2/en not_active Expired - Fee Related
- 2006-12-27 KR KR1020087018439A patent/KR20080114683A/ko not_active Ceased
- 2006-12-27 RU RU2008130893/13A patent/RU2008130893A/ru not_active Application Discontinuation
- 2006-12-27 EP EP11176754A patent/EP2390372A1/en not_active Withdrawn
- 2006-12-27 AU AU2006342053A patent/AU2006342053A1/en not_active Abandoned
- 2006-12-27 CN CN200680053371.XA patent/CN101389768B/zh not_active Expired - Fee Related
- 2006-12-27 MX MX2008008453A patent/MX2008008453A/es active IP Right Grant
- 2006-12-27 EP EP06851054.4A patent/EP1977009B1/en active Active
- 2006-12-27 JP JP2008548837A patent/JP2009521707A/ja active Pending
- 2006-12-27 BR BRPI0620755-3A patent/BRPI0620755A2/pt not_active Application Discontinuation
- 2006-12-27 CA CA002635269A patent/CA2635269A1/en not_active Abandoned
-
2008
- 2008-10-24 US US12/257,967 patent/US7910310B2/en not_active Expired - Fee Related
- 2008-10-24 US US12/257,937 patent/US7745110B2/en not_active Expired - Fee Related
-
2011
- 2011-02-07 US US13/022,219 patent/US20110189235A1/en not_active Abandoned
-
2013
- 2013-08-14 US US13/966,631 patent/US20130323273A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006342053A1 (en) | 2007-10-25 |
| KR20080114683A (ko) | 2008-12-31 |
| US20130323273A1 (en) | 2013-12-05 |
| US7910310B2 (en) | 2011-03-22 |
| US20110189235A1 (en) | 2011-08-04 |
| EP2390372A1 (en) | 2011-11-30 |
| MX2008008453A (es) | 2008-11-28 |
| BRPI0620755A2 (pt) | 2011-11-22 |
| US20090087455A1 (en) | 2009-04-02 |
| US20090087833A1 (en) | 2009-04-02 |
| WO2007120362A3 (en) | 2008-08-14 |
| CA2635269A1 (en) | 2007-10-25 |
| EP1977009A2 (en) | 2008-10-08 |
| US20070218081A1 (en) | 2007-09-20 |
| WO2007120362A2 (en) | 2007-10-25 |
| EP1977009B1 (en) | 2016-08-17 |
| US7442511B2 (en) | 2008-10-28 |
| CN101389768A (zh) | 2009-03-18 |
| US7745110B2 (en) | 2010-06-29 |
| JP2009521707A (ja) | 2009-06-04 |
| EP1977009A4 (en) | 2009-06-03 |
| CN101389768B (zh) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Devaux et al. | ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome | |
| CA2635269A1 (en) | Adipogenic adenoviruses as a biomarker for disease | |
| Filmus et al. | Glypican‐3: a marker and a therapeutic target in hepatocellular carcinoma | |
| JP7260248B2 (ja) | 細胞透過性抗体 | |
| CN109765378B (zh) | 一种新的肝硬化或肝纤维化标志物 | |
| DE69922261D1 (de) | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten | |
| USRE42129E1 (en) | Viral obesity methods and compositions | |
| ATE419516T1 (de) | Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc) | |
| EP3364987A1 (en) | Prognosis and treatment of squamous cell carcinomas | |
| JP7522918B2 (ja) | 抗hmmw抗体、それを含む組成物、及びそれをコードする核酸分子、並びにその使用 | |
| CN1849136A (zh) | 癌症疾病改善抗体 | |
| CN113395976A (zh) | 良性肿瘤的预防或治疗药 | |
| CN102257138B (zh) | 肿瘤抗原肽及其用途 | |
| RU2011127868A (ru) | Связанный с раком толстого кишечника ген том34 | |
| JP2001522599A (ja) | 診断用及びワクチン用、c型肝炎ウイルスエンベロープタンパク質由来マルチマーペプチド | |
| JP2003522774A (ja) | 異種型抗体療法の効力の診断のための方法 | |
| WO2011030300A1 (en) | Synthetic peptides from the sv40 t-antigen for use in an indirect elisa test for the identification of antibodies against simian virus 40 in human serum and other fluids | |
| CN111139299A (zh) | Josd2蛋白在制备治疗恶性肿瘤药物中的应用 | |
| CN109022462B (zh) | 一种PTEN基因的上游开放阅读框31aa-uORF核苷酸及其编码的多肽的应用 | |
| JP2022513152A5 (cg-RX-API-DMAC7.html) | ||
| JP3524536B2 (ja) | 癌の診断、モニタリング、ステージング、イメージングおよび処置のための新規方法 | |
| EP1705487A2 (en) | Method of diagnosing, monitoring, staging, imaging and treating colon cancer | |
| WO2018156645A1 (en) | Preventative cancer therapy | |
| EP3088000A1 (en) | Vaccine targeting il-17a | |
| CN121154805A (zh) | 单克隆抗体MPXV-mAb 975和MPXV-mAb 981的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110117 |